This study investigated the expression of the water channel protein aquaporin-9 (AQP9) in 100 cases of human astrocytic tumour compared with normal brain tissue. AQP9 mRNA and protein were assessed using reverse transcriptionpolymerase chain reaction and Western blot, respectively. The expression of both AQP9 mRNA and protein in astrocytic tumours was significantly greater than in normal brain tissue and was positively correlated with pathological grade. No significant correlations were found between the level of AQP9 mRNA or protein expression and gender, age, tumour size or tumour site. This study indicates that AQP9 may play an important role in the malignant progression of brain astrocytic tumours and may, therefore, be useful as a biomarker in its diagnosis and as a new target for gene therapy. The molecular mechanisms by which AQP9 affects the proliferation and apoptosis of astrocytic tumours need to be studied further.
Introduction
Aquaporins (AQPs) are a family of integral membrane water channel proteins that facilitate the rapid transport of water across cell membranes in response to osmotic gradients. 1, 2 It has previously been shown that the expression of aquaporin-9 (AQP9) changes in some pathological situations. 3, 4 In this study the expression of AQP9 and its correlation with pathological grade was investigated in 100 human brain astrocytic tumours.
Patients and methods

PATIENTS AND TUMOUR SPECIMENS
Patients with primary brain astrocytic tumours surgically treated at the Neurosurgical Department, First Hospital Affiliated to Chongqing Medical University, Chongqing, China, from January 2004 to December 2007 were included in this study. None of the patients had received chemotherapy or radiotherapy before the operation. Histopathological diagnosis of tumour specimens was made on the basis of G Tan, SQ Sun, DL Yuan Aquaporin-9 and pathological grade in astrocytic tumours standard haematoxylin and eosin staining and was performed by different neuropathologists. Pathological grades and histological subtypes were defined according to the 2000 World Health Organization criteria. 5 Normal brain tissue specimens were obtained as control comparators from the specimen bank of Chongqing Medical University.
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Department of Medical Research, Chongqing Medical University. Informed consent was obtained directly from each patient or from their family members if the patient's state of consciousness prevented direct patient consent.
EXPRESSION OF AQP9 MRNA
The expression of AQP9 mRNA was assessed using a reverse transcription-polymerase chain reaction. Total RNA from both tumour and normal brain specimens was isolated using TRIzol ® reagent (Invitrogen, Carlsbad, CA, USA). First-strand complementary DNA synthesis was performed using Superscript III Reverse Transcriptase (Invitrogen) to transcribe poly(A) + RNA with oligo(dT) 18 as the primer. Polymerase chain reaction (PCR) was performed using a Taq DNA polymerase kit (TaKaRa, Dalian, China). The sequences of PCR primers used for the AQP9 gene were 5′-GAAGGACGGTGCCAAGAAG-3′ (forward) and
5′-GTGATGATCCCGCCAAAAC-3′ (reverse), giving rise to a specific band of 165 base pairs (bp). The internal loading control was β-actin; the PCR primers used were 5′-CTGCCGCATCCTCTTCCTC-3′ (forward) and 5′-CTCCTGCTTGCTGATCCACAT-3′ (reverse), giving a specific band of 398 bp.
Standard PCR was performed using 1 × PCR buffer (final concentration) (TaKaRa), 260 µM deoxynucleoside triphosphates, 2 µM of each primer and 2.5 units of Taq polymerase in a total volume of 25 µl. The PCR reactions were performed as follows: initial denaturation at 94°C for 3 min, then 30 cycles of denaturation at 94°C for 30 s, annealing at 62.5°C for 30 s (the annealing temperature for β-actin was 58°C) and elongation at 72°C for 30 s, followed by a 5 min extension at 72°C and cooling to 4°C. Then 10 µl of PCR product was subjected to electrophoresis on 1.5% agarose gel.
EXPRESSION OF AQP9 PROTEIN
Expression of AQP9 protein was assessed using Western blot analysis. The tumour and normal brain specimens were homogenized in radioimmunoprecipitation assay lysis buffer comprising 50 mmol/l Tris-HCl (pH 7.5), 150 mmol/l sodium choride, 1% Nonidet™ P40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS) and a cocktail of protease inhibitors (Sigma-Aldrich, St Louis, MO, USA), and then centrifuged at 10 000 g for 20 min at room temperature. The supernatant was collected, further dissolved in the urea-containing buffer (TaKaRa) and separated using electrophoresis on a 12% SDS-polyacrylamide gel. Protein concentration was determined using a Bradford assay kit (Bio-Rad, Hercules, CA, USA). After gel electrophoresis, the protein was transferred onto nitrocellulose membranes and immunolabelled at room temperature overnight with polyclonal rabbit anti-AQP9 antiserum (Alpha Diagnostics International, San Antonio, TX, USA). The membranes were then incubated at room temperature for 30 min with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The specific reaction was visualized using a chemiluminescent substrate (Pierce, Rockford, IL, USA). G Tan, SQ Sun, DL Yuan Aquaporin-9 and pathological grade in astrocytic tumours
STATISTICAL ANALYSIS
Statistical analyses were performed using the SAS 9.1 software package (SAS Institute, Cary, NC, USA). The means ± SD levels of AQP9 protein and mRNA expression were calculated. Differences in AQP9 expression in specimens of different pathological grades were first compared using analysis of variance (ANOVA); thereafter, Tamhane's T2 test was used to compare differences between the two groups produced by ANOVA. Correlation coefficients of AQP9 expression and pathological grade were evaluated using Pearson's correlation analysis. All the reported P-values were two-sided, and a Pvalue < 0.05 was considered to be statistically significant.
Results
A total of 100 patients (58 men and 42 women) aged 8 -74 years with primary brain astrocytic tumours were included in this study. Of these, 19 cases were grade I (16 pilocytic astrocytomas and three subependymal giant cell astrocytomas), 29 cases were grade II (22 diffuse fibrillary astrocytomas, three protoplasmic astrocytomas, one gemistocytic astrocytoma and three pleomorphic xanthoastrocytomas), 27 cases were grade III (all anaplastic astrocytomas) and 25 cases were grade IV (all glioblastomas). Tumour size was < 4 cm in 46 cases and ≥ 4 cm in the other 54 cases. Sixty-eight tumours were located supratentorially, while the other 32 were 
EXPRESSION OF AQP9 MRNA
All 100 tumour specimens and 15 normal brain specimens expressed AQP9 mRNA (Fig. 1A) . The expression of AQP9 mRNA in astrocytic tumours was significantly greater for all pathological grades than normal (control) brain tissue (P < 0.05 for grade I; P < 0.01 for grades II, III and IV). AQP9 mRNA expression also increased with ascending pathological grade (Fig. 1B) , showing a significant positive correlation (r = 0.934, P < 0.05). Mean ± SD levels of AQP9 mRNA in tumour tissues were as follows (percentage relative to control):
235.7% ± 9.85% (grade I), 386.4% ± 13.82% (grade II), 461.3% ± 22.39% (grade III) and 523.1% ± 32.43% (grade IV). The significant differences between the pathological grades are shown in Fig. 1B . No significant correlations were found between the level of AQP9 mRNA expression and gender, age, tumour size or tumour site.
EXPRESSION OF AQP9 PROTEIN
All 100 tumour specimens and 15 normal brain specimens expressed AQP9 protein ( Fig. 2A) . As for mRNA, the expression of AQP9 protein in astrocytic tumours was significantly greater for all pathological grades than normal (control) brain tissue (P < 0.05 for grade I; P < 0.01 for grades II, III and IV) and showed a significant positive G Tan, SQ Sun, DL Yuan Aquaporin-9 and pathological grade in astrocytic tumours correlation with ascending pathological grade (r = 0.846, P < 0.05) (Fig. 2B ). Mean ± SD levels of AQP9 protein in tumour tissues were as follows (percentage relative to control): 154.2% ± 12.63% (grade I), 227.5% ± 16.51% (grade II), 343.8% ± 20.80% (grade III) and 464.2% ± 38.22% (grade IV). The significant differences between the pathological grades are shown in Fig. 2B . No significant correlations were found between the level of AQP9 protein expression and gender, age, tumour size or tumour site.
Discussion
The AQPs are integral membrane proteins that serve as selective pathways for water transport across the plasma membranes of many tissues and cell types. Ten AQPs have been identified, each with a characteristic distribution, in the kidney, liver, lung, eye and brain. 6 -9 AQP9 is a member of the aquaporin channel family involved in water flux through plasma membranes and exhibits the distinct feature of also being permeable to monocarboxylates such as lactate, and to various solutes including glycerol, carbamides, purines, pyrimidines and urea. AQP9 is constitutively expressed at high levels in the liver. In the brain under physiological conditions, AQP9 was first observed in tanycytes and then in astrocytes. 10 Jablonski et al. 11 reported that AQP9 expression is significantly decreased in hepatocellular carcinoma compared with normal liver. A study by Badaut et al. 9 suggested that AQP9 may also play a role in the regulation of post-ischaemia oedema and, in view of its permeability to monocarboxylates, in the clearance of lactate from the ischaemic focus. In the case of astrocytic tumours, Warth et al. 12 showed increased AQP9 expression in glioma compared with normal brain using immunohistochemistry but they did not study AQP9 mRNA expression.
In the present study, the expressions of AQP9 mRNA and protein in tumour specimens were both significantly increased compared with normal brain tissue for all grades of astrocytic tumours and it is noteworthy that AQP9 mRNA and protein expression in high-grade tumours was greater than that in low-grade ones. Furthermore, the correlations between the expression of AQP9 protein and mRNA and pathological grade suggest that AQP9 expression in brain astrocytic tumours is closely related to severity.
Although the mechanisms contributing to this phenomenon need to be further explored, the hypothesis has been put forward that the water channel is involved in energy metabolism of malignant glioma cells. 12 The underlying mechanism for the expression of AQP9 in astrocytic tumours of different pathological grades remains to be elucidated.
In summary, the present study has indicated that AQP9 may play an important role in the malignant progression of brain astrocytic tumours, acting as a useful biomarker for molecular diagnosis and a new target for gene therapy. The molecular mechanisms by which AQP9 affects the proliferation and apoptosis of astrocytic tumours need to be studied further.
